Author:
Shaw Katharina S.,Hashemi Kimberly B.,Castillo Rochelle L.,Rainone Elizabeth,Ho Allen W.,Kahn Philip J.,Oza Vikash S.,Femia Alisa,Vleugels Ruth Ann
Reference5 articles.
1. Factors associated with clinical remission of skin disease in dermatomyositis;Wolstencroft;JAMA Dermatol,2018
2. Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment;Shaw;JAMA Dermatol,2024
3. Refractory dermatomyositis responsive to anifrolumab;Ang;JAAD Case Rep,2023
4. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis;Huard;Br J Dermatol,2017
5. Safety, tolerability, and pharmacokinetics of PF-06823859, an anti-interferon β monoclonal antibody: a randomized, phase I, single- and multiple-ascending-dose study;Neelakantan;Clin Pharmacol Drug Dev,2021